Mirabegron Stada (Mirabegron)

Mirabegron selectively activates β3‑adrenergic receptors in the bladder’s detrusor muscle. This activation raises cyclic AMP levels, leading to muscle relaxation, increased storage capacity, and fewer involuntary contractions that cause urgency and leakage.

The appropriate dose of Mirabegron Stada is determined by the prescribing healthcare professional based on the patient’s condition, renal function, and other clinical factors. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for mirabegron in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To request Mirabegron Stada, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Mirabegron offers an alternative mechanism by targeting β3‑adrenergic receptors, whereas antimuscarinics block muscarinic receptors. This difference can result in a lower incidence of dry mouth and constipation, but individual response and side‑effect profiles vary, so clinicians choose based on patient tolerance and comorbidities.

Mirabegron Stada tablets should be stored at ambient temperature below 25 °C. Keep them in the original container, protect from moisture and direct sunlight, and ensure they are out of reach of children.

Mirabegron Stada is taken orally, usually once daily with or without food, as directed by the prescriber. Swallow the tablet whole with water; do not crush, split, or chew unless specifically instructed.

Serious risks include significant hypertension, tachycardia, acute urinary retention, angioedema, and rare cardiac arrhythmias such as QT prolongation. Patients should report any sudden increase in blood pressure, rapid heartbeat, difficulty urinating, or swelling of the face or throat immediately.

Mirabegron Stada is contraindicated in patients with uncontrolled hypertension, severe renal impairment, or known hypersensitivity to mirabegron or any tablet excipients. Caution is also advised for individuals with narrow‑angle glaucoma or those taking medications that significantly affect blood pressure or cardiac rhythm.